Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 38 | SFEBES2015 | Next issue

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Card image cap
2-4 November 2015, Edinburgh, UK Further information

Oral Communications

Translational pathophysiology and therapeutics

ea0038oc2.1 | Translational pathophysiology and therapeutics | SFEBES2015

Dual 5-α reductase inhibition promotes hepatic lipid accumulation in man as a result of changes to lipid metabolism in adipose tissue and the liver

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Guida Riccardo Di , Grinbergs Annabel , Davies Nigel , Flintham Robert , Armstrong Matthew , Taylor Angela , Hughes Beverly , Yu Jinglei , Hodson Leanne , Dunn Warwick , Tomlinson Jeremy

Background and aims: 5α reductase 1 and 2 (SRD5A1 (expressed in liver and adipose), SRD5A2 (expressed in liver) inactivate cortisol to 5α-dihydrocortisol in addition to their role in the generation of dihydrotestosterone and therefore regulate the tissue availability of cortisol. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and Finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic effects have only recently been identified....

ea0038oc2.2 | Translational pathophysiology and therapeutics | SFEBES2015

Adrenal vein catecholamine levels and ratios: reference intervals derived from patients with primary aldosteronism

O'Toole Sam , Sze Candy , Tirador Kent , Akker Scott , Matson Matthew , Perry Les , Druce Maralyn , Dekkers Tanja , Deinum Jaap , Lenders Jacques , Eisenhofer Graeme , Drake William

Introduction: Phaeochromocytoma localisation is generally reliably achieved with modern imaging techniques, particularly in sporadic cases. Diagnostic doubt can arise due to the presence of bilateral adrenal abnormalities, particularly in patients with mutations in genes predisposing them to the phaeochromocytoma development. In such cases, surgical intervention is ideally limited to large or functional lesions due to the long-term consequences associated with hypoadrenalism. ...

ea0038oc2.3 | Translational pathophysiology and therapeutics | SFEBES2015

Further advances in diagnosis of adrenal cancer: a high-throughput urinary steroid profiling method using liquid chromatography tandem mass spectrometry (LC-MS/MS)

Taylor Angela , Bancos Irina , Chortis Vasileios , Lang Katharina , O'Neil Donna , Hughes Beverly , Jenkinson Carl , Deeks Jon , Shackleton Cedric , Biehl Michael , Arlt Wiebke

Context: Differentiating adrenocortical adenoma (ACA) from adrenocortical carcinoma (ACC) represents a continuous challenge in patients with (often incidentally discovered) adrenal masses, with unfavorable sensitivities and specificities provided by tumor size, imaging and even histology. We have previously developed urine steroid metabolomics as a tool for the detection of adrenal malignancy employing gas chromatography mass spectrometry (GC-MS) for the detection of 32 distin...

ea0038oc2.4 | Translational pathophysiology and therapeutics | SFEBES2015

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Speak Rowena , Pradhananga Sarbendra , Justice Sue , Ross Richard , Wilkinson Ian

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). This is because many patients do not respond to somatostatin therapy. Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). There is therefore an unmet need for a cost-effective GHA. We have developed a fusion technology for making a cost-effective long-a...

ea0038oc2.5 | Translational pathophysiology and therapeutics | SFEBES2015

Age at first major osteoporotic fracture in Danes aged 50 and over: influence of diabetes on mean age at fracture and 1 year mortality

Abrahamsen Bo , Rosengren Bjorn , Prieto-Alhambra Daniel , Napoli Nicola , Cooper Cyrus

Diabetes mellitus (DM) is associated with an increased risk of fractures in excess of what would be expected from age and BMD. Further, DM is associated with increased risk of mortality in patients with hip fractures and possibly also other osteoporotic fractures.Study population and methods: Patients aged 50 or over who were treated for fractures of the hip, forearm, humerus and spine over 6 years (2004–2009, n=146 256) not coded as road t...

ea0038oc2.6 | Translational pathophysiology and therapeutics | SFEBES2015

Treatment with the epigenetic modifying compound JQ1+ can significantly reduce the proliferation of pancreatic neuroendocrine tumours in a mouse model of multiple endocrine neoplasia type 1

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Muller Susanne , Knapp Stefan , Bountra Chas , Thakker Rajesh V

There are currently no curative treatments for metastatic pancreatic neuroendocrine tumours (PNETs), and the 5-year survival is <50%. Such tumours frequently have mutations in chromatin remodelling genes as well as the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin, which is mutated in up to 40% of sporadic PNETs, and binds the histone methyltransferase MLL1. Histone modifications, and specifically acetylated residues on histone tail...